Nancy L. Bartlett, MD

Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma

Purpose of the Study: Axicel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved by the US Food and Drug Administration for the treatment of patients with r...

Sattva S. Neelapu ;

Javier Munoz ;

Olalekan O. Oluwole ;

Caron A. Jacobson ;

Abhinav Deol ;

David B. Miklos ;

Nancy L. Bartlett , MD;

Ira Braunschweig ;

Yizhou Jiang ;

Jenny J. Kim ;

Lianging Zheng ;

John M. Rossi ;

Frederick L. Locke ;

10/22/2019

Magrolimab in Combination With Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 3-Year Follow-up Results From a Phase 1/2 Trial

Introduction:

Ian W. Flinn ;

Nancy L. Bartlett , MD;

Amitkumar Mehta ;

Nilanjan Ghosh , MD, PhD;

Leslie Popplewell ;

Carol O'Hear ;

Yanan Huo ;

Indu Lal ;

Bertha Villa ;

Graham P Collins ;

Ranjana Advani ;

Sonali M. Smith , MD;

Mark Roschewski , MD;

11/04/2022

How Do I Approach Upfront Early Stage Hodgkin Lymphoma?

Nancy L. Bartlett , MD;

10/26/2019

What is the best upfront approach for the treatment of advanced stage HL? ABVD

Nancy L. Bartlett , MD;

10/20/2018

BTK Inhibitors in B-Cell Malignancies: Opportunities and Challenges

Nancy L. Bartlett , MD;

10/20/2018

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Nancy L. Bartlett, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products